title: [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
abstract: METHODS
  A 69-year-old woman with small cell lung cancer presented in the emergency ward because of severe back pain. She had received tolvaptan treatment in hospital for paraneoplastic SIADH but had discontinued the drug after discharge from hospital 3 days ago. Restriction of fluid intake was not tolerated.
  
  
  METHODS
  Consistent with SIADH, there were profound hyponatraemia, elevated urine osmolality and urine sodium.
  
  
  METHODS
  After a generalized seizure triggered by hyponatraemia, tolvaptan was reintroduced in addition to radiochemotherapy. Serum sodium concentration increased and finally returned to normal.
  
  
  CONCLUSIONS
  If restriction of fluid intake is not tolerated by the patients the vasopressin antagonist tolvaptan provides an alternative symptomatic treatment of paraneoplastic SIADH.
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München.
authors.forename: A
authors.initials: A
authors.lastname: Schnaiter
authors.affiliation: Medizinische Klinik und Poliklinik III, Klinikum der Universität München.
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
mesh_terms: D000368:Aged; D065092:Antidiuretic Hormone Receptor Antagonists / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D010257:Paraneoplastic Syndromes / Q000150:complications* / Q000188:drug therapy*; D055752:Small Cell Lung Carcinoma / Q000150:complications* / Q000188:drug therapy*; D000077602:Tolvaptan; D016896:Treatment Outcome
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan